Client Overview
A German-headquartered pharmaceutical company operating in the vitaminic therapeutic space needed to renew its Marketing Authorization (MA) in Mexico — a market where product continuity depends entirely on proactive regulatory management. With no in-country regulatory presence, the client faced a critical exposure: COFEPRIS's renewal process requires not just documentation, but a certified local pharmacovigilance unit (UPV) and active lifecycle coordination that global teams operating from European time zones cannot manage on their own. The client turned to Freyr LATAM to serve as its local regulatory arm — not just for the renewal itself, but for the full spectrum of compliance obligations attached to it.
Background
Mexico's regulatory framework under COFEPRIS is precise and unforgiving on timelines. A Marketing Authorization renewal is not a passive administrative process — it requires alignment between the global dossier and local format standards, active pharmacovigilance representation, and timely submission of safety reports. Any gap in these obligations can trigger objections, delays, or, in the worst case, interruptions to product commercialization.
For multinational companies managing large portfolios across multiple markets, Mexico often becomes a risk point precisely because it demands in-country regulatory capacity that centralized global teams cannot reliably provide. That structural gap — between global operations and local COFEPRIS requirements — was the core challenge this engagement was designed to close.
Services in Scope
Technical review of existing documentation against COFEPRIS format and content requirements
Identification and remediation of gaps prior to submission
Certified local UPV representation under COFEPRIS guidelines
Preparation and submission of the Periodic Safety Report (PR)
Validation of all regulatory components under updated national guidelines
End-to-end submission management with zero-objection target
Sustained communication and alignment with global regulatory affairs teams across time zones
Seamless integration into the client's existing international RA operations model
Challenge
The complexity of this engagement was not in any single requirement — it was in the simultaneity of obligations, each with its own timeline and its own consequence if missed.
Tight submission deadlines: COFEPRIS renewal timelines operate with little buffer, and any delay in documentation preparation directly compresses the submission window.
Dossier format misalignment: The client's global dossier did not fully conform to COFEPRIS's local format requirements — a gap that had to be identified and corrected before submission, not during agency review.
UPV requirement: Mexican regulation mandates a certified local pharmacovigilance unit. Without one, the MA renewal cannot proceed — making the UPV appointment a prerequisite, not a parallel workstream.
No in-country presence: With no local regulatory team, the client depended entirely on Freyr LATAM to serve as its operational anchor in Mexico — managing agency coordination, documentation, and communications in real time.
Solution
1
Freyr LATAM deployed a dedicated local team and conducted a technical gap analysis to identify misalignments between the client's existing documentation and COFEPRIS's current requirements — establishing a clear remediation plan before the submission clock started.
2
Freyr assumed the role of certified Pharmacovigilance Unit (UPV) in Mexico, fulfilling the mandatory local representation requirement and taking full ownership of pharmacovigilance compliance for the duration of the engagement.
3
The Periodic Safety Report (PR) was prepared and submitted within COFEPRIS deadlines, with all content validated against current national pharmacovigilance guidelines.
4
All regulatory components of the MA renewal dossier were validated under updated COFEPRIS guidelines and submitted as a complete, objection-ready package — designed for first-cycle approval.
5
Throughout the engagement, Freyr LATAM maintained consistent, structured communication with the client's global RA teams — bridging time zone differences and ensuring that local decisions were always aligned with international regulatory strategy.
Impact
Freyr LATAM's intervention converted a high-risk renewal process into a controlled, predictable regulatory outcome. The 5-year MA was secured on the first submission cycle with zero objections, zero market disruption, and a strengthened compliance foundation that positions the client for future regulatory activity across Mexico and the broader LATAM region.
5-year MA renewal secured with zero regulatory objections on first submission cycle
Zero disruption to product commercialization throughout the renewal process
Proactive gap analysis eliminated documentation misalignment before submission
Certified UPV representation established — full pharmacovigilance compliance met
Periodic Safety Report prepared and submitted within COFEPRIS deadlines
Strengthened regulatory platform for future submissions and LATAM expansion
